1. Academic Validation
  2. Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

Substituted 1,2,4-Triazoles as Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

  • ACS Omega. 2023 Aug 18;8(34):31293-31304. doi: 10.1021/acsomega.3c03682.
Abdurrahman Olğaç 1 2 İrfan Çapan 3 Philipp Dahlke 4 Paul M Jordan 4 Oliver Werz 4 Erden Banoglu 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Yenimahalle 06560 ,Ankara ,Turkey.
  • 2 Department of Drug Discovery, Evias Pharmaceutical R&D Ltd., Yenimahalle06830 ,Ankara ,Turkey.
  • 3 Department of Material and Material Processing Technologies Technical Sciences Vocational College, Gazi University, Yenimahalle06374 ,Ankara ,Turkey.
  • 4 Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Philosophenweg 14, D-7743 Jena, Germany.
Abstract

5-Lipoxygenase-activating protein (FLAP) is a regulator of cellular leukotriene biosynthesis, which governs the transfer of arachidonic acid (AA) to 5-lipoxygenase for efficient metabolism. Here, the synthesis and FLAP-antagonistic potential of fast synthetically accessible 1,2,4-triazole derivatives based on a previously discovered virtual screening hit compound is described. Our findings reveal that simple structural variations on 4,5-diaryl moieties and the 3-thioether side chain of the 1,2,4-triazole scaffold markedly influence the inhibitory potential, highlighting the significant chemical features necessary for FLAP antagonism. Comprehensive metabololipidomics analysis in activated FLAP-expressing human innate immune cells and human whole blood showed that the most potent analogue 6x selectively suppressed leukotriene B4 formation evoked by Bacterial exotoxins without affecting other branches of the AA pathway. Taken together, the 1,2,4-triazole scaffold is a novel chemical platform for the development of more potent FLAP antagonists, which warrants further exploration for their potential as a new class of anti-inflammatory agents.

Figures
Products